IAP6 Recorect/Pto GO3 APR 200/

PATENT ATTORNEY DOCKET NO. 50026/059001

Certificate of Mailing: Date of Dep	posit: <u>March 27, 2007</u>
I hereby certify under 37 C.F.R. § 1.8(a) that this corresp Service as first class mail with sufficient postage on the Commissioner for Patents, P.O. Box 1450, Alexandria, V	date indicated above and is addressed to Mail Stop PCT,
Megan Kiley Printed name of person mailing correspondence	Signature of person mailing/correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Iwadate et al.

Confirmation No.:

4667

Serial No.:

10/585,884

Art Unit:

Not Yet Assigned

Filed:

July 12, 2006

Examiner:

Not Yet Assigned

Customer No.:

21559

Title:

GENE THERAPY FOR TUMORS USING MINUS-STRAND RNA

VIRAL VECTORS ENCODING IMMUNOSTIMULATORY

CYTOKINES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application and is also enclosed.

Applicants note that JP 2000-253876, WO 97/16539 A1, WO 00/01837 A1, WO 00/70055 A1, WO 00/70070A1, WO 02/31138 A1, WO 03/025570 A1, WO 03/029475 A1, WO 03/102183 A1, WO 04/022731 A1, and WO 04/038029 A1 are written in the

10585884 - GAU:

Japanese language, except for the English language abstract. English language

translations of these publications are enclosed.

JP 58-157723 A, JP 7-503455 A, and Hasegawa ("Shinki Idenshi Chiryoyo Vector

No Kaihatsu," The Cell (Saibou) 33(6): 227-231 (2001)), are written in the Japanese

language. In accordance with 37 C.F.R. § 1.98(a)(3), enclosed is an English language

search report listing JP 58-157723 A, JP 7-503455 A, and Hasegawa ("Shinki Idenshi

Chirvoyo Vector No Kaihatsu," The Cell (Saibou) 33(6): 227-231 (2001)).

Submission of this statement is not a representation that a search has been made,

nor is the inclusion of information in this statement an admission that the information is

material to patentability.

This statement is being filed before the receipt of a first Office action on the

merits.

If there are any charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 27 March 2007

James D. DeCamp, Ph.D.

Reg. No. 43,580

JAN N. TITTER, P.L.D.

Pley. No. 52,290

Clark & Elbing LLP 101 Federal Street

Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

2

Sheet <u>1</u> of <u>3</u>

(37 C.F.R. § 1.98(b))		IDS Filed	March 27, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Group	Not yet assigned
		Filing Date	July 12, 2006
		Applicant	lwadate et al.
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/585,884
SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50026/059001

		U.S. PATE	NT DOCUMENTS	
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Filing Date (If Appropriate)
/M.W./	10/578,085			May 3, 2006
	2002/0012995 A1	Jan. 31, 2002	Fukumura et al.	
880000	2002/0169306 A1	Nov. 14, 2002	Kitazato et al.	
3000000000	2003/0022376 A1	Jan. 30, 2003	Kitazato et al.	
000000000000000000000000000000000000000	2003/0166252 A1	Sep. 4, 2003	Kitazato et al.	
	2003/0170266 A1	Sep. 11, 2003	Kitazato et al.	
000	2005/0266566 A1	Dec. 1, 2005	Nagai et al.	
000000000000000000000000000000000000000	2005/0271628 A1	Dec. 8, 2005	Fukumura et al.	
00000	2007/0009949 A1	Jan. 11, 2007	Kitazato et al.	
V	6,645,760 B2	Nov. 11, 2003	Nagai et al.	
/M.W./	6,723,532 B2	Apr. 20, 2004	Nagai et al.	

		FOREIG	N PATENT OR PUBLI	SHED FOREIGN PATENT APPLICATION	
Examin Initia		Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
/M.	W./	EP 0 864 645 A1	Sep. 16, 1998	EPO	
		JP 58-157723 A	Sep. 19, 1983	Japan	No
		JP 7-503455 A	Apr. 13, 1995	Japan	No
		JP 2000-253876	Sep. 19, 2000	Japan	Yes
N	/	WO 97/16539 A1	May 9, 1997	WIPO	Yes
/M.	.W./	WO 00/01837 A1	Jan. 13, 2000	WIPO	Yes

EXAMINER	/Michael Wilson/ (02/25/2008)	DATE CONSIDERED	02/25/2008
	itial citation considered. Draw line through citation ext communication to applicant.	on if not in conformance and	not considered. Include copy of this

Sheet 2 of 3

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50026/059001
(MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,884
		Applicant	lwadate et al.
		Filing Date	July 12, 2006
		Group	Not yet assigned
(37 C.F.R. § 1.98(b))		IDS Filed	March 27, 2007

	FOREIG	N PATENT OR PUBLI	SHED FOREIGN PATENT APPLICATION	
/M.W./	WO 00/70055 A1	Nov. 23, 2000	WIPO .	Yes
	WO 00/70070 A1	Nov. 23, 2000	WIPO	Yes
	WO 02/31138 A1	Apr. 18, 2002	WIPO	Yes
	WO 02/38726 A2	May 16, 2002	WIPO	
00000000	WO 03/025570 A1	Mar. 27, 2003	WIPO .	Yes
000000000	WO 03/029475 A1	Apr. 10, 2003	WIPO	Yes
0000000	WO 03/102183 A1	Dec. 11, 2003	WIPO	Yes
V	WO 04/022731 A1	Mar. 18, 2004	WIPO	Yes
/M.W./	WO 04/038029 A1	May 6, 2004	WIPO	Yes

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
/	Bitzer et al., "Sendai Virus Vectors as an Emerging Negative-Strand RNA Viral Vector System," J. Gen. Med. 5(7): 543-553 (2003).
	Bitzer et al., "Negative-strand RNA Viral Vectors: Intravenous Application of Sendai Virus Vectors for the Systemic Delivery o Therapeutic Genes," <i>Mol. Ther.</i> 7(2): 210-217 (2003).
	Boviatsis et al., "Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovit Vectors," Hum. Gene Ther. 5(2): 183-191 (1994).
	Giezeman-Smits et al., "Cytokine Gene Therapy of Gliomas: Induction of Reactive CD4 ⁺ T Cells by Interleukin-4-Transfected Gliosarcoma Is Essential for Protective Immunity," <i>Cancer Res.</i> 60(9): 2449-2457 (2000).
	Hasegawa, "Shinki Idenshi Chiryoyo Vector No Kaihatsu," The Cell (Saibou) 33(6): 227-231 (2001).
	Herrlinger et al., "Vaccination for Experimental Gliomas using GM-CSF-Transduced Glioma Cells," Cancer Gene Ther. 4(6): 345-352 (1997).
	Inoue et al., "Matrix and Fusion Genes-Deficient Sendai Virus Vector: Efficient Gene Transfer with Preferable Properties," Matrix 5(5): S174-S175, Abstract #530 (2002).
./	Inoue et al., "Recombinant Sendai Virus Vectors Deleted in both the Matrix and the Fusion Genes: Efficient Gene Transfer w Preferable Properties," <i>J. Gene Med.</i> 6(10): 1069-1081 (2004).

EXAMINER /Michael Wilson/ (02/25/2008)

DATE CONSIDERED

02/25/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMM		Attorney Docket No.	50026/059001
(MODIFIED) PATENT AND TRADEMARK OFFICE		Serial No.	10/585,884
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	lwadate et al.
		Filing Date	July 12, 2006
		Group	Not yet assigned
(37 C.F.R. § 1.98(b))		IDS Filed	March 27, 2007

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
N	Iwadate et al., "Induction of Acquired Immunity in Rats that have Eliminated Intracranial Gliosarcoma Cells by the Expression of Herpes Simplex Virus-Thymidine Kinase Gene and Ganciclovir Administration," <i>Oncology</i> 54(4): 329-334 (1997).
	lwadate et al., "Immunological Responsiveness to Interleukin-2-Producing Brain Tumors can be Restored by Concurrent Subcutaneous Transplantation of the Same Tumors," <i>Cancer Gene Ther.</i> 7(9): 1263-1269 (2000).
	Iwadate et al., "Induction of Immunity in Peripheral Tissues Combined with Intracerebral Transplantation of Interleukin-2-Producing Cells Eliminates Established Brain Tumors," <i>Cancer Res.</i> 61(24): 8769-8774 (2001).
	Iwadate et al., "Interleukin-12-Mediated Induction of Systemic Immunity in the Periphery and Recruitment of Activated T Cells into the Brain Produce Limited Antitumor Effects Compared with Interleukin-2," <i>Int. J. Mol. Med.</i> 10(6): 741-747 (2002).
	Iwadate et al., "Glioma-Specific Cytotoxic T Cells can be Effectively Induced by Subcutaneous Vaccination of Irradiated Wild-Type Tumor Cells without Artificial Cytokine Production," <i>Int. J. Oncol.</i> 23(2): 483-488 (2003).
	Kramm et al., "Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy," <i>Hum. Gene Ther.</i> 8(17): 2057-2068 (1997).
	Li et al., "A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression," J. Virol. 74(14): 6564-6569 (2000).
	Ram et al., "In Situ Retroviral-Mediated Gene Transfer for the Treatment of Brain Tumors in Rats," Cancer Res. 53(1): 83-88 (1993).
	Ram et al., "In Vivo Transfer of the Human Interleukin-2 Gene: Negative Tumoricidal Results in Experimental Brain Tumors," J. Neurosurg. 80(3): 535-540 (1994).
	Ram et al., "Therapy of Malignant Brain Tumors by Intratumoral Implantation of Retroviral Vector-Producing Cells," <i>Nat. Med.</i> 3(12): 1354-1361 (1997).
	Saleh et al., "Effect of <i>In Situ</i> Retroviral Interleukin-4 Transfer on Established Intracranial Tumors," <i>J. Natl. Cancer Inst.</i> 91(5): 438-445 (1999).
	Sampson et al., "Subcutaneous Vaccination with Irradiated, Cytokine-Producing Tumor Cells Stimulates CD8 ⁺ Cell-Mediated Immunity Against Tumors Located in the "Immunologically Privileged" Central Nervous System," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93(19): 10399-10404 (1996).
	Shapiro, "Current Therapy for Brain Tumors," Arch. Neurol. 56(4): 429-432 (1999).
	Shirakura et al., "Sendai Virus Vector-Mediated Gene Transfer of Glial Cell Line-Derived Neurotrophic Factor Prevents Delayed Neuronal Death after Transient Global Ischemia in Gerbils," <i>Exp. Anim.</i> 52(2): 119-127 (2003).
V.	Suzuki et al., "Feeding Suppression by Fibroblast Growth Factor-1 is Accompanied by Selective Induction of Heat Shock Protein 27 in Hypothalamic Astrocytes," <i>Eur. J. Neurosci.</i> 13(12): 2299-2308 (2001).
	Unternational Search Report for PCT/JP2005/000238, mailed April 26, 2005

DATE CONSIDERED /Michael Wilson/ (02/25/2008) **EXAMINER** EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

02/25/2008